Researchers discovered that an immunotherapy, called anti-CTLA-4, mobilizes microglia against glioblastoma as it causes CD4+ T cell infiltration of the brain. A study led by Salk Institute (CA, USA) ...

Interestingly, CTLA-4 knockout mice and mice that lack expression of CTLA-4 just in T REG develop fatal, early-onset lymphoproliferative disease. 1,4 In addition, expression and signaling of CTLA ...

Xilio expects to report updated data from the Phase 2 clinical trial in the middle of 2025, including additional response assessments and follow-up. In addition, Xilio continues to enroll patients in ...

The claims of all three patents are directed to methods of treating cancer with the combination of two checkpoint inhibitor immunotherapeutic antibodies, anti-PD-1 and anti-CTLA-4.

Scientists find immunotherapy anti-CTLA-4 extends life of mice with glioblastoma and discover new way cells kill cancer. In a murine study, scientists have identified a biomarker that may help ...

Reports Q4 revenue $1.724M vs $0 last year. “We started 2025 with multiple promising updates across our pipeline, including encouraging initial ...

Combination treatment with cadonilimab and lenvatinib can produce responses in patients with advanced endometrial cancer.